Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 4/20 | 0.57 |
| ▸ | KDM6B | O15054 | 2/20 | 0.57 |
| ▸ | LATS1 | O95835 | 4/20 | 0.46 |
| ▸ | AOC1 | P19801 | 6/20 | 0.45 |
| ▸ | AOC3 | Q16853 | 5/20 | 0.45 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.41 |
| ▸ | ECE1 | P42892 | 1/20 | 0.40 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.40 |
| ▸ | LATS2 | Q9NRM7 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | RAD52 | P43351 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8241807 | 0.85 | KDM4C (0.53) | KDM4CKDM6BLATS1AOC1AOC3 | |
| SCHEMBL2268998 | 0.85 | AOC1 (0.61) | KDM4CKDM6BLATS1AOC1AOC3 | |
| SCHEMBL14576594 | 0.81 | PTGER4 (0.46) | KDM4CKDM6BAOC1AOC3GAA | |
| SCHEMBL9978099 | 0.81 | AOC1 (0.41) | KDM4CKDM6BAOC1AOC3GAA | |
| SCHEMBL740267 | 0.78 | PTGER4 (0.44) | KDM4CKDM6BAOC1AOC3GAA | |
| SCHEMBL10310091 | 0.78 | KDM4C (0.61) | KDM4CKDM6BLATS1AOC1AOC3 | |
| Pyridine SCHEMBL7022106 | 0.77 | AOC1 (0.53) | KDM4CKDM6BLATS1AOC1AOC3 | |
| SCHEMBL9426618 | 0.76 | HTT (0.51) | KDM4CKDM6BGAA | |
| SCHEMBL18857746 | 0.75 | KDM4C (0.43) | KDM4CKDM6BLATS1ECE1MUS81 | |
| Hydrochloric Acid SCHEMBL7652650 | 0.75 | KDM6B (0.61) | KDM4CKDM6BAOC3GAAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140024621-A1 | AMINOPYRIDINE COMPOUNDS AND THEIR USES | MS THERAPEUTICS LIMITED (GB) | 2014-01-23 | — | — | US | disclosed |
| EP-1368342-B3 | BENZIMIDAZOLE AND PYRIDYLIMIDAZOLE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | NEUROGEN CORP (US) | 2010-12-01 | — | — | EP | disclosed |
| US-20100267698-A1 | Benzimidazole and Pyridylimidazole Derivatives | NEUROGEN CORPORATION | 2010-10-21 | — | — | US | disclosed |
| US-7642267-B2 | Benzimidazole and pyridylimidazole derivatives | NEUROGEN CORPORATION (US) | 2010-01-05 | — | — | US | disclosed |
| US-20080227793-A1 | Benzimidazole and Pyridylimidazole Derivatives | NEUROGEN CORPORATION | 2008-09-18 | — | — | US | disclosed |
| US-7300945-B2 | Benzimidazole and pyridylimidazole derivatives | NEUROGEN CORPORATION (US) | 2007-11-27 | — | — | US | disclosed |
| US-20060025425-A1 | Benzimidazole and pyridylimidazole derivatives | NEUROGEN CORPORATION | 2006-02-02 | — | — | US | disclosed |
| EP-1368342-B1 | BENZIMIDAZOLE AND PYRIDYLIMIDAZOLE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | NEUROGEN CORP (US) | 2005-09-07 | — | — | EP | disclosed |
| US-6916819-B2 | Benzimidazole and pyridylimidazole derivatives | NEUROGEN CORPORATION (US) | 2005-07-12 | — | — | US | disclosed |
| US-20030069257-A1 | Benzimidazole and pyridylimidazole derivatives | NEUROGEN CORPORATION | 2003-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267698-A1 | Benzimidazole and Pyridylimidazole Derivatives | GABBR1, GABBR2, GABRA2 | KDM4C 1488/4885KDM6B 2163/4885LATS1 3934/4885 |
| US-20080227793-A1 | Benzimidazole and Pyridylimidazole Derivatives | GABBR1, GABBR2, GABRA2 | KDM4C 1488/4885KDM6B 2163/4885LATS1 3934/4885 |
| US-20060025425-A1 | Benzimidazole and pyridylimidazole derivatives | GABBR1, GABBR2, GABRA2 | KDM4C 1488/4885KDM6B 2163/4885LATS1 3934/4885 |
| US-20140024621-A1 | AMINOPYRIDINE COMPOUNDS AND THEIR USES | DNPEP, PEPD, ANPEP | KDM4C 678/4885KDM6B 914/4885LATS1 2657/4885 |
| US-20030069257-A1 | Benzimidazole and pyridylimidazole derivatives | GABBR1, GABRA1, GABBR2 | KDM4C 1364/4885KDM6B 2153/4885LATS1 4035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.